RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Jun 14, 2025--
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-rocket-pharmaceuticals-inc-class-action-lawsuit-rckt.html
You can also contact attorneysJ.C. SanchezorJennifer N. Caringalof Robbins Geller by calling 800/449-4900 or via e-mail at[email protected].
CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint.
The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250613610226/en/
CONTACT: Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL
SOURCE: Robbins Geller Rudman & Dowd LLP
Copyright Business Wire 2025.
PUB: 06/14/2025 10:30 AM/DISC: 06/14/2025 10:28 AM
http://www.businesswire.com/news/home/20250613610226/en

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

8 minutes ago

• Bloomberg

Fed's Daly Says Central Bank Communication Should Be Flexible

Federal Reserve Bank of San Francisco President Mary Daly said central bankers need to communicate with flexibility at times of uncertainty, given that using strong forward guidance sometimes 'comes with a price.' 'The economy is dynamic, and our communications must match it,' Daly said Sunday in a speech prepared for the Western Economic Association International's 100th Annual Conference. Daly didn't comment on the outlook for the economy or policy in her written remarks, which she also said were not about the Fed's ongoing framework review.

TechCrunch

13 minutes ago

• TechCrunch

Moratorium on state AI regulation clears Senate hurdle

A Republican effort to prevent states from enforcing their own AI regulations cleared a key procedural hurdle on Saturday. The rule, as reportedly rewritten by Senate Commerce Chair Ted Cruz in an attempt to comply with budgetary rules, would withhold federal broadband funding from states if they try to enforce AI regulations in the next 10 years. And the rewrite seems to have passed muster, with the Senate Parliamentarian now ruling that the provision is not subject to the so-called Byrd rule — so it can be included in Republicans' 'One Big, Beautiful Bill' and passed with a simple majority, without potentially getting blocked by a filibuster, and without requiring support from Senate Democrats. However, it's not clear how many Republicans will support the moratorium. For example, Republican Senator Marsha Blackburn of Tennessee recently said, 'We do not need a moratorium that would prohibit our states from stepping up and protecting citizens in their state.' And while the House of Representatives already passed a version of the bill that included a moratorium on AI regulation, far-right Representative Marjorie Taylor Greene subbsequently declared that she is 'adamantly OPPOSED' the provision as 'a violation of state rights' and said it needs to be 'stripped out in the Senate.' House Speaker Mike Johnson defended the provision by saying it had President Donald Trump's support and arguing, 'We have to be careful not to have 50 different states regulating AI, because it has national security implications, right?' In a recent report, Americans for Responsible Innovation (an advocacy group for AI regulation), wrote that 'the proposal's broad language could potentially sweep away a wide range of public interest state legislation regulating AI and other algorithmic-based technologies, creating a regulatory vacuum across multiple technology policy domains without offering federal alternatives to replace the eliminated state-level guardrails.' Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW A number of states do seem to be taking steps toward AI regulation. In California, Governor Gavin Newsom vetoed a high-profile AI safety bill last year while signing a number of less controversial regulations around issues like privacy and deepfakes. In New York, an AI safety bill passed by state lawmakers is awaiting Governor Kathy Hochul's signature. And Utah has passed its own regulations around AI transparency.

Wall Street Journal

22 minutes ago

• Wall Street Journal

Bank of New York Mellon Approached Northern Trust to Discuss Potential Merger

Bank of New York Mellon BK 0.02%increase; green up pointing triangle approached Northern Trust last week to express interest in merging with its smaller rival, people familiar with the matter said, in what would be a monster deal for the financial-services industry. The chief executives of BNY and Northern Trust had at least one conversation, the people said, though the firms didn't discuss a specific offer.